James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Why Seattle Genetics, Inc. (SGEN), Endologix, Inc. (ELGX) and Amphastar Pharmaceuticals Inc (AMPH) Are 3 of Today’s Worst Stocks

Owners of healthcare stocks Endologix (ELGX), Amphastar Pharmaceuticals (AMPH) and Seattle Genetics (SGEN) each had a run of bad luck on Tuesday.

7 Stocks That Won’t Be Around a Year From Now

Not every corporation is going to survive the coming year... at least not as the stocks they are today.

Nokia Corp (ADR) (NOK) Stock Just Walked Back Into Another Endless Pit

Nokia stock is a lot of things, but it's not a play on cell phones ... at least not a good one. Here's why NOK stock owners shouldn't celebrate just yet.

Trump’s Shot at Lockheed Martin Corporation (LMT) Is More Bark Than Bite

Lockheed Martin (LMT) doesn't really have anything to worry about, other than perhaps a little embarrassment over its F-35 debacle.

Why Twilio Inc (TWLO), Gap Inc (GPS) and Red Hat Inc (RHT) Are 3 of Today’s Worst Stocks

Gap (GPS), Twilio (TWLO) and Red Hat (RHT) never even had a prayer of bullish progress on Thursday. Here's what investors need to know.